Advances in vaccine manufacturing – a step toward recombinant production

The existence of viruses poses a great threat to society as the population of the world rises. Infection from specific types of viruses can arise from sanitary conditions and demographics of the continent; making vaccination the most effective way to prevent the development of an infection.

Two hundred and fifty million doses of influenza vaccines are designed, manufactured, distributed and administered each year [1]. These doses are brought to market in more than 100 countries. The advancements in genetic engineering has led to a divergence from live cell cultures to recombinant production in host cells. This minimizes the risk of handling live viruses, reduces production times and targeted strain engineering can optimize the product titer and quality.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.


Leave A Comment